Experiment 68819

Details

PropertyValue
Pharmacology
Administration routeRECTAL
OrganismSerenoa repens (ARECACEAE)
CitationBERNARDI DI VALSERRA,MD: TRIPODI,AS:. (1994). RECTAL BIOAVAILABILITY AND PHARMACOKINETICS IN HEALTHY VOLUNTEERS OF SERENOA REPENS. NEW FORMULATION.. 46()
Amount utilized
Compound isolated
DiseaseTHE BIOAVAILABILITY AND PHARMACOKINETIC PROFILE OF A NEW DEVELOPED 640 MG RECTAL SERENOA REPENS EXTRACT PREPARATION WERE DETERMINED IN 12 HEALTHY MALE VOLUNTEERS. DRUG WAS ADMINISTERED AT DOSE OF 640 MG, BLOOD SAMPLES WERE COLLECTED AT 0.5-1.5-2-3-4-6-8 AND 10 HOURS AFTER, AND PLASMA CONCENTRATIONS OF SERENOA REPENS 2ND COMPONETS WERE QUANTIFIED BY A HPLC-METHOD. MEAN MAXIMUM CONCENTRATION OF 2ND COMPONENT IN PLASMA OF NEARLY 2.60 UG/ML ABOUT 3 HOURS AFTER DRUG INTAKE WITH MWAN VALUE FOR THE AREA UNDER THE CURVE AUC OF 10UG*H/ML WERE OBSERRVED. THE BIOAVAILABILITY AND PHARMACOKINETIC PROFILE OF A 640 MG RECTAL SERENOA REPENS ADMINISTRATION, ONLY T(MAX) OCCURRED ABOUT 1 H LATER AND SERENOA REPENS 2ND COMPONENT PLASMA CONCENTRATION 8 HOURS AFTER DRUG ADMINISTRATION WAS STILL QUANTIFIED. THE DRUG TOLERABILITY WAS GOOD AND NO ADVERSE EFFECT WERE OBSERVED.
Dose amount640.0 MG
Number1
Qualitative resultACTIVE
AnimalHUMAN ADULT
Per unitDAY
Dose expressionDOSE
ExtractFIXED OIL
GenderMALE